Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) EBIAT (2016 - 2025)

Protalix BioTherapeutics has reported EBIAT over the past 16 years, most recently at -$5.5 million for Q4 2025.

  • Quarterly results put EBIAT at -$5.5 million for Q4 2025, down 184.76% from a year ago — trailing twelve months through Dec 2025 was -$6.6 million (down 325.24% YoY), and the annual figure for FY2025 was -$6.6 million, down 325.24%.
  • EBIAT for Q4 2025 was -$5.5 million at Protalix BioTherapeutics, down from $2.4 million in the prior quarter.
  • Over the last five years, EBIAT for PLX hit a ceiling of $19.3 million in Q2 2023 and a floor of -$11.2 million in Q2 2021.
  • Median EBIAT over the past 5 years was -$3.6 million (2022), compared with a mean of -$1.9 million.
  • Biggest five-year swings in EBIAT: plummeted 2196.54% in 2021 and later soared 462.56% in 2023.
  • Protalix BioTherapeutics' EBIAT stood at -$6.7 million in 2021, then skyrocketed by 43.9% to -$3.7 million in 2022, then crashed by 61.6% to -$6.0 million in 2023, then surged by 207.45% to $6.5 million in 2024, then plummeted by 184.76% to -$5.5 million in 2025.
  • The last three reported values for EBIAT were -$5.5 million (Q4 2025), $2.4 million (Q3 2025), and $164000.0 (Q2 2025) per Business Quant data.